Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NKGen Biotech, Inc. (NKGN : OTC)

• Company Description    NKGen Biotech Inc. is a clinical-stage biotechnology company. It focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies. NKGen Biotech Inc., formerly known as Graf Acquisition Corp. IV, is based in THE WOODLANDS, Texas. Number of Employees: 63

• Price / Volume Information    Yesterday's Closing Price: $0.30 Daily Weekly Monthly 20 Day Moving Average: 136,551 shares Shares Outstanding: 44.95 (millions) Market Capitalization: $13.48 (millions) Beta: 1.26 52 Week High: $1.37 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.11% -14.44% 12 Week 135.29% 97.91% Year To Date -54.21% -57.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3001 DAIMLER STREET - SANTA ANA,CA 92705 USA ph: 949-396-6830 fax: - investors@nkgenbiotech.com http://www.nkgenbiotech.com

• General Corporate Information    Officers Paul Y. Song - Chief Executive Officer and Director James Graf - Interim Chief Financial Officer Sangwoo Park - Director Michael Klowden - Director Kathleen Scott - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65488A101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 09/11/25 Share - Related Items Shares Outstanding: 44.95 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $13.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 106.05% vs. Previous Quarter: 122.39% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©